Skip to main content

Table 2 Patient clinical characteristics and response evaluation

From: Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study

Patient ID

Gender

Age at time of chemotherapy (years)

Diagnosis

NR4A3 rearrangement

Site of primary tumor

Staging at time of initial diagnosis

Site of relapse at the time of chemotherapy

RECIST evaluation

PFS

1

F

48

EMC

yes

thigh

localized disease

abdomen, LN

PR

7*

2

M

56

EMC

yes

thigh

localized disease

lung, LN

PD

4

3

M

46

EMC

yes

thigh

local + lung

lung, LN

PR

8

4

M

38

EMC

yes

leg

localized disease

lung, bone, liver, soft tissue

NV

2

5

M

55

EMC

yes

leg

localized disease

lung, LN, soft tissue

PR

8

6

F

64

EMC

yes

thigh

localized disease

lung

SD

10

7

M

69

EMC

yes

buttock

local + lung

buttock, lung

PR

5*

8

M

55

EMC

yes

arm

local + lung

lung, LN

SD

7

9

M

51

EMC

yes

thigh

localized disease

lung

PD

4

10

M

52

EMC

yes

leg

localized disease

lung

SD

5*

11

M

48

EMC

yes

sacrum

local + lung

lung

PD

3

  1. *Patient treated with surgery after chemotherapy, censored at the time of surgical resection; M, male; F, female; EMC, extraskeletal myxoid chondrosarcoma; LN, lymphonode; PR, partial response; SD, stable disease; PD, progressive disease; NV, not evaluable; PFS, progression free survival.